Jefferies upgraded Rigel Pharmaceuticals (RIGL) to Buy from Hold with a $42 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Midday Fly By: Broader market bought on dip after tech selloff
- Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald
- Rigel Pharmaceuticals Reports Strong Q3 2025 Results
- Rigel Pharmaceuticals reports Q3 EPS $1.46, consensus 94c
- Rigel Pharmaceuticals raises FY25 revenue view to $285M-$290M from $270M-$280M